No longer left to its own devices in putting Afrezza inhaled insulin on the market, Exubera-haunted Mannkind Corp. landed an eagerly awaited commercialization deal with Sanofi SA that brings $150 million up front and as much as $775 million in regulatory, development and sales milestone payments for the second-generation product.